Euroasian journal of hepato-gastroenterology

Register      Login

VOLUME 6 , ISSUE 2 ( July-December, 2016 ) > List of Articles

RESEARCH ARTICLE

Role of Renin–Angiotensin-converting Enzyme Level and ACE Gene Polymorphism in Patients with Nonalcoholic Fatty Liver Disease

Demet D Tekatas, Ibrahim H Bahcecioglu, Murat Ispiroglu, Abdurrahman Sahin, Necip Ilhan, Mehmet Yalniz, Ulvi Demirel

Citation Information : D Tekatas D, H Bahcecioglu I, Ispiroglu M, Sahin A, Ilhan N, Yalniz M, Demirel U. Role of Renin–Angiotensin-converting Enzyme Level and ACE Gene Polymorphism in Patients with Nonalcoholic Fatty Liver Disease. Euroasian J Hepatogastroenterol 2016; 6 (2):137-142.

DOI: 10.5005/jp-journals-10018-1186

License: CC BY-NC 4.0

Published Online: 01-05-2010

Copyright Statement:  Copyright © 2016; The Author(s).


Abstract

Introduction: In this study, we aimed to investigate the histological and clinical effect of angiotensinconverting enzyme (ACE) and ACE gene polymorphism in nonalcoholic fatty liver disease (NAFLD) and their roles in the progression of the disease. Materials and methods: Liver function tests, body mass index, waist circumference, lipid parameters, fasting blood glucose (FBG), hemoglobin A1c (HbA1c), homeostasis model assessment-IR (HOMA-IR), ACE, and ACE gene polymorphism were evaluated in the NAFLD group and control group. The study group was evaluated by dividing the group into four subgroups by ACE gene polymorphism (D/D homozygous, I/I homozygous, D/I heterozygous, I/D heterozygous). Liver biopsies were evaluated according to Brunt Classification. Results: A total of 31 patients who were diagnosed with NAFLD and 40 healthy individuals were included in the study. The ACE level was found to be 11.69 ± 1.99 in the NAFLD group and 11.52 ± 1.72 in the control group (p = 0.70). There was a negative correlation between ACE levels and HOMA-IR levels (p = 0.008, r= −0.512). Biochemical parameters were not different among ACE gene polimorphism subgroups, except FBG (between D/D, I/D and D/I, I/D; p = 0.02). When the ACE levels were compared in terms of grade and stage, no significant difference was found (for stage and grade p = 0.68). The ACE gene polymorphism subgroups did not differ by histopathologic findings; grade and stage (for grade p = 0.42, for stage p = 0.92). Conclusion: In this study, we could not find a correlation of ACE and ACE gene polymorphism with metabolic risk factors and the disease severity in NAFLD.


PDF Share
  1. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004 Jun;39(6):1647-1654
  2. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21(1):27-41. Demet D Tekatas et al 142 3. Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/ non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004 Dec;18(6):1089-1104
  3. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002 Feb 7;346(6):393-403
  4. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005 Feb;54(2):303-306
  5. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr Phrama Des 2003;9(12):1023-1031
  6. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006 Apr;17(1):4-12
  7. Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells. Chin Med J 2008 Jan 20;121(2):161-165
  8. Liver fibrosis: a balance of ACEs? Clin Sci 2007 Aug;113(3):109-118
  9. The renin-angiotensin system and its receptors. J Cardiovasc Pharmacol 1999;33 (Suppl 1):S21-S28
  10. Angiotensinconverting enzyme in the human heart. Effect of the deletion/ insertion polymorphism. Circulation 1995;92(6):1387-1388
  11. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990 Oct;86(4):1343-1346
  12. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 1992 Mar 25;20(6):1433
  13. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet 2001 May;68(5): 1139-1148
  14. Angiotensin II type 1 receptor interaction is an important regulator for the development of pancreatic fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 2004 Jul;287(1):G170-G177
  15. The ACE gene I/D polymorphism does not affect the susceptibility to or prognosis of PBC. Turk J Gastroenterol 2008 Dec;19(4):250-253
  16. The functional angiotensin converting enzyme gene I/D polymorphism does not alter susceptibility to chronic pancreatitis. JOP J Pancreas 2004;5(6):457-463
  17. Angiotensin-converting enzyme insertion/deletion gene polymorphism in inflammatory bowel diseases. Eur J Gastroenterol Hepatol 2007 Nov;19(11):976-981
  18. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 2009 Apr;49(4):1132-1140
  19. Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C. Hepatol Res 2009 Aug;39(8):795-804
  20. Nonalcoholic fatty liver disease. Gastroenterology 2002 May;122(6):1649-1657
  21. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002 Mar;34(3):255-262
  22. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999 Dec;30(6):1356-1362
  23. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scan J Gastroenterol 2005 Dec;40(12):1469-1477
  24. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989 Jun;20(6):594-598
  25. Fatty liver – an additional and treatable feature of the insulin resistance syndrome. QJM 1999 Feb;92(2):73-79
  26. Nonalcoholic steatohepatitis. Semin Liver Dis 1999;19(2):221-229.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.